Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment

Newsylist Editorial Desk. (2026, September 7, 2026). Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-09-07/integration-of-proteomic-aging-clocks-in-a-phase-2a-clinical-trial-supports

@online{newsylist_48321,
  author = {Newsylist Editorial Desk},
  title = {{Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-09-07/integration-of-proteomic-aging-clocks-in-a-phase-2a-clinical-trial-supports},
  note = {Tracked across 1 independent newsrooms}
}

> According to Newsylist Editorial Desk ([Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment](https://www.newsylist.com/trend/2026-09-07/integration-of-proteomic-aging-clocks-in-a-phase-2a-clinical-trial-supports)), this event was corroborated across 1 independent sources with a live velocity of 0.